Elotuzumab for Treatment of Multiple Myeloma (Literature Review)

Chemotherapy has been the main treatment option for multiple myeloma for several decades. However, a considerable increase in the life expectancy was observed in multiple myeloma patients when thalidomide, bortezomib and lenalidomide had been introduced into clinical practice. Nevertheless, the dise...

Full description

Saved in:
Bibliographic Details
Main Author: OM Votyakova
Format: Article
Language:Russian
Published: Practical Medicine Publishing House 2016-10-01
Series:Клиническая онкогематология
Subjects:
Online Access:http://bloodjournal.ru/en/elotuzumab-for-treatment-of-multiple-myeloma-literature-review/
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849685853020880896
author OM Votyakova
author_facet OM Votyakova
author_sort OM Votyakova
collection DOAJ
description Chemotherapy has been the main treatment option for multiple myeloma for several decades. However, a considerable increase in the life expectancy was observed in multiple myeloma patients when thalidomide, bortezomib and lenalidomide had been introduced into clinical practice. Nevertheless, the disease remains incurable and there is an unmet need in fundamentally new treatment methods. Elotuzumab is a humanized IgG1 monoclonal antibody that specifically targets SLAMF7, an antigen belonging to the signaling lymphocytic activation molecule family, with its high expression detected on myeloma cells. This review presents the mechanism of action of elotuzumab, preclinical data and the main clinical studies of this monoclonal antibody.
format Article
id doaj-art-c78ac88cbb084e2987635e6a0503a6cb
institution DOAJ
issn 1997-6933
2500-2139
language Russian
publishDate 2016-10-01
publisher Practical Medicine Publishing House
record_format Article
series Клиническая онкогематология
spelling doaj-art-c78ac88cbb084e2987635e6a0503a6cb2025-08-20T03:22:57ZrusPractical Medicine Publishing HouseКлиническая онкогематология1997-69332500-21392016-10-019443844510.21320/2500-2139-2016-9-4-438-445Elotuzumab for Treatment of Multiple Myeloma (Literature Review)OM Votyakova0NN Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478Chemotherapy has been the main treatment option for multiple myeloma for several decades. However, a considerable increase in the life expectancy was observed in multiple myeloma patients when thalidomide, bortezomib and lenalidomide had been introduced into clinical practice. Nevertheless, the disease remains incurable and there is an unmet need in fundamentally new treatment methods. Elotuzumab is a humanized IgG1 monoclonal antibody that specifically targets SLAMF7, an antigen belonging to the signaling lymphocytic activation molecule family, with its high expression detected on myeloma cells. This review presents the mechanism of action of elotuzumab, preclinical data and the main clinical studies of this monoclonal antibody.http://bloodjournal.ru/en/elotuzumab-for-treatment-of-multiple-myeloma-literature-review/monoclonal antibodieselotuzumabclinical studiesmultiple myeloma
spellingShingle OM Votyakova
Elotuzumab for Treatment of Multiple Myeloma (Literature Review)
Клиническая онкогематология
monoclonal antibodies
elotuzumab
clinical studies
multiple myeloma
title Elotuzumab for Treatment of Multiple Myeloma (Literature Review)
title_full Elotuzumab for Treatment of Multiple Myeloma (Literature Review)
title_fullStr Elotuzumab for Treatment of Multiple Myeloma (Literature Review)
title_full_unstemmed Elotuzumab for Treatment of Multiple Myeloma (Literature Review)
title_short Elotuzumab for Treatment of Multiple Myeloma (Literature Review)
title_sort elotuzumab for treatment of multiple myeloma literature review
topic monoclonal antibodies
elotuzumab
clinical studies
multiple myeloma
url http://bloodjournal.ru/en/elotuzumab-for-treatment-of-multiple-myeloma-literature-review/
work_keys_str_mv AT omvotyakova elotuzumabfortreatmentofmultiplemyelomaliteraturereview